Join us for a special BCBB summer networking reception at Cafe ArtScience in Kendall Square courtesy of Vertex with free food and open bar.
Wednesday July 24th at 5:30PM, the computational biology group from Vertex Pharmaceuticals will be hosting a special summer edition of the meetup. Come join your comp bio and bioinformatics colleagues from across the greater Boston area for a night of comp bio shop talk and networking. Thanks to Vertex, for the first time in the history of BCBB we’ll have not only free food but also an open bar for the beginning of the event. Vertex has some great comp bio positions available, see below for details.
All computational biologists and bioinformaticians are welcome regardless of skill level, from lifelong hardcore professionals and academics to people who are starting to think about learning just enough programming to make science go faster. See old friends, mentors, students, and make new connections while sharing tales of comp bio triumph and woe over free drinks and food.
This is a very special BCBB event, if you’ve thought about joining us in the past but haven’t made it yet, this is the one to be at.
We’ll be in the private event space (The Honeycomb) at Cafe ArtScience, conveniently located in the heart of Kendall Square — ask for Boston Comp Bio at the host stand when you arrive.
The Computational Genomics group at Vertex Pharmaceuticals is hiring!
We have two openings for research scientists to join our team focused on developing novel, innovative gene editing and genetic therapy treatments of serious human diseases. One position is tailored for individuals who love working collaboratively and applying computational methods to discover novel insights to biological questions. The other position is tailored for experts in developing novel computational methods and tools. We are looking for positive, self-motivated, and bright individuals to join our fun and supportive team. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease, and we are co-sponsors of the first clinical trial for a CRISPR treatment with CTX-001, to treat Sickle Cell Disease and B-thalassemia. Please visit our postings at http://bit.ly/vrtxCG1 and http://bit.ly/vrtxCG2 to apply!